Reneuron Share Discussion Threads

[ayl30] 12/2/2021 09:03

Nice vol this am

[the stigologist] 11/2/2021 20:09

Good set up .

[dickbush] 11/2/2021 11:30

Lauders, many thanks for that article. RENE's management has mentioned the possibility of its exosomes being useful in fighting COVID-19, but I thought it was just a try on to boost the share price.

Now, if today's announcement of increased options is, heaven forbid, related to this article in the Times of Israel, we may see those option targets realised a lot sooner than 3 years.

I can dream...

[latifs100] 11/2/2021 10:20

cant get a live quote

[deutsch4] 11/2/2021 09:22

Keeps going from full cream to semi-skinned and eventually fully skimmed - pretty soon it won't colour your tea!

[dickbush] 11/2/2021 08:34

Agreed. As Boards tend to set targets they expect to satisfy, I view this as very good news. Nice work if you can get it, though, particularly for the CEO and CFO.

[the stigologist] 11/2/2021 08:10

Very nice option vesting target

Stock has to triple!

[ayl30] 10/2/2021 17:19

Another tick up day. Market is starting to pay some attention

[felix99] 10/2/2021 08:33

hxxps://www.cityam.com/israeli-hospital-says-it-may-have-found-covid-19-cure-as-all-treated-patients-make-full-recovery/?utm_content=bufferb68fa

Is this relevant to RENE?

Thanks

[the stigologist] 08/2/2021 19:14

Chart seems to be ready to turn after retesting the breakout resistance level as support

[lauders] 07/2/2021 01:35

Hmm.... Interesting. If this makes its way into the widestream media it may generate more interest in exesomes and thereby benefit RENE: A protein known as CD24 is delivered to the lungs by exosomes in the drug, which helps to rebalance the immune system and prevent it from overreacting to the virus.

However, should'nt it be "drug in the exosomes", not the other way round?

[rayrac] 06/2/2021 10:27

Same could be said of you?😂 well, changed perhaps? Any link to the interview?

[wonker26] 06/2/2021 05:54

Great interview by Michael Hunt. I assume he doesn’t abbreviate his first name.......

[rayrac] 05/2/2021 22:56

More than a technical bounce for me. Sounds rather bullish on prospects for Rene! Pleased to be a small participant in its future.

[the stigologist] 05/2/2021 12:42

Think it's just a technical bounce as it retested downtrend line we broke out of

Maybe Myles McNulty finished his selling to buy 4D ?

We are overdue news on the Pharma collaborations 'promised' for Q1 if not january

[loafofbread] 05/2/2021 12:18

Not one to ramp but something coming down the tracks?

[loafofbread] 05/2/2021 10:29

Interesting buying going on.

Long may it continue!

[small crow] 02/2/2021 17:46

Must hurt.

[loafofbread] 01/2/2021 22:57

Schroder UK Public Private Tst plc Agreement for sale of assets
27/01/2021 7:00am
UK Regulatory (RNS & others)

Woodford Patient Capital (LSE:WPCT)
Historical Stock Chart

From Jan 2021 to Feb 2021

Click Here for more Woodford Patient Capital Charts.
TIDMSUPP

RNS Number : 9819M

Schroder UK Public Private Tst plc

27 January 2021

Schroder UK Public Private Trust plc (the "Company")

Agreement for sale of assets

The Company (LSE: SUPP) is pleased to announce that it has signed a sale and purchase agreement for the sale of a basket of seven assets (the "Sale Portfolio") to Rosetta Capital VI, LP (the "Buyer"), an investment fund managed by the UK-based life science venture capital firm Rosetta Capital Limited, for a total acquisition price of GBP49.0 million (the "Transaction"). The Sale Portfolio consists of the Company's entire holdings in Carrick Therapeutics, Mission Therapeutics, PsiOxus Therapeutics and Mereo BioPharma and partial holdings in Inivata, Immunocore and ReNeuron. The agreed acquisition price represents a discount of 22 per cent to the aggregate valuation for those holdings reflected in the Q3 2020 Net Asset Value ("NAV") as at 30 September 2020 (as published on 3 December 2020) or a discount of 19% per cent adjusted for relevant foreign exchange rate changes as of 25 January 2021.

The Buyer has also agreed to pay approximately GBP2.9 million to the Company representing the value of certain follow-on investments made by the Company with respect to holdings contained in the Sale Portfolio during January 2021. In total, the Company expects to receive initial proceeds from the Transaction of approximately GBP51.9 million.

Furthermore, given the recent news of Immunocore filing for an initial public offering ("IPO"), the Company has agreed with the Buyer an earn-out under which the Company might receive an additional contingent payment of up to GBP5.0 million subject to the Immunocore stake acquired by the Buyer exceeding certain value thresholds at the Buyer's future exit of the investment. The Company had previously agreed to a lock-up period under which it would not sell its entire holding for a period of 6 months from the date of the IPO. The Buyer has agreed to be bound by the restrictions of a lock-up agreement on the same terms as the Company. The Company will remain subject to the lock-up for the proportion of the holding it is retaining.

In addition, the Company and the Buyer have agreed to a potential adjustment to the acquisition price in the event of significant changes in value of the listed portfolio companies Mereo BioPharma and ReNeuron on an aggregated basis by the date of completion of the Transaction. The Company does not currently expect the potential acquisition price adjustment, if any, to be significant in the context of the overall transaction.

The closing of the Transaction is subject to customary closing conditions. The Company expects the completion to occur in late February or March 2021.

The valuation impact of the Transaction is expected to be reflected in the NAV of the Company as at 31 December 2020, which is expected to be announced in April 2021.

A significant proportion of the expected proceeds will be used to pay down a meaningful portion of the Company's outstanding debt under its credit facility whereby the current term loan will convert to a revolving credit facility. In addition, the Company intends to use the additional liquidity to support some of its portfolio companies with follow-on capital and further optimise the portfolio composition by selectively investing into new opportunities

Tim Creed and Ben Wicks, Portfolio Managers of the Company, jointly commented: "After the announcement of the acquisition of Kymab by Sanofi and the extension of the Company's credit facility by two years, this is the third very positive announcement for the Company so far in 2021. When we assumed the management of the Company's investment portfolio in December 2019, we communicated that our initial focus in the process of repositioning the portfolio would be to reduce the outstanding debt to a sustainable level and put the Company back into a position to support its portfolio companies with follow-on capital and selectively make new investments. The basket transaction being announced today is a further important milestone for the Company and delivers against that communicated goal. Together with the divestiture of Kymab, the Company expects to receive total proceeds of more than GBP115 million by the end of the first half of 2021. Also, we are delighted to welcome Rosetta Capital as co-shareholders in ReNeuron, Immunocore and Inivata and we welcome their expertise and experience. We are looking forward to continuing to work with the management teams of the Company's holdings in delivering sustainable value and positive long-term shareholder returns."

Susan Searle, Chair of the Board of the Company, commented: "I am extremely pleased with the progress that Schroders have made since taking over the management of the portfolio. The three announcements made in 2021; the extension of our debt facility, a significant portfolio company cash exit and a portfolio sale put the Company in a solid position from which to grow in 2021. These events reflect the hard work of the team throughout 2020 and I look forward to seeing the team build on this encouraging positive progress in repositioning the Company's portfolio."

Enquiries:

Schroder Investment Management Limited

[algernon2] 01/2/2021 14:52

I wouldn't call him dull Stig, he is very clear and straightforward with maybe just a touch of "dour" thrown in to the mix.
Had hoped the RP stuff might get to market before the projected 2024/2025 that he predicts in the video.
I am hoping for some news on the Exosomes front long long before then.

[the stigologist] 27/1/2021 21:09

RENE due to present tomorrow but a Conf related video out now

www.vimeo.com/498431522

[volsung] 27/1/2021 16:20

Bought a few more for 113p

[the stigologist] 18/1/2021 20:15

Golden Cross rapidly approaching

[the stigologist] 18/1/2021 12:51

With US market closed a good day to push this story to a bored US bio #FinTwit audience

[hashertu] 18/1/2021 09:32

Algernon2. Let's hope detritus does not get used as a badge of honour in the next US election.